- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07689994
Evaluation of the Effect of a Seaweed Flour- and Leucine-Enriched Food on Metabolic and Inflammatory Status in Older Adults With Probable Sarcopenia or Sarcopenia
Evaluation of the Effect of a Seaweed Flour- and Leucine-Enriched Food on Metabolic and Inflammatory Status in Older Adults With Probable Sarcopenia or Sarcopenia: A Prospective, Controlled, Randomized, Double-Blind, Three-Arm Parallel Clinical Trial
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Sarcopenia is a progressive skeletal muscle disorder associated with aging and an increased risk of disability, hospitalization, dependency, and mortality. Contemporary consensus definitions identify low muscle strength as the primary characteristic of the condition, while muscle quantity or quality and physical performance are used to support the diagnosis and determine its severity.
In older adults, anabolic resistance reduces the muscle's responsiveness to habitual dietary protein intake. Leucine has been proposed as an amino acid capable of stimulating key anabolic pathways and therefore represents a plausible candidate for short-term nutritional interventions. In turn, Durvillaea incurvata flour provides bioactive compounds and dietary fiber with potential antioxidant and anti-inflammatory properties, although clinical evidence supporting its use in sarcopenia remains limited.
From a methodological perspective, a 28-day follow-up period may be sufficient to detect early metabolic and nutritional responses, but it may be insufficient to demonstrate robust clinical changes in muscle strength, muscle mass, or physical performance. For this reason, serum TTR has been selected as the primary short-term response outcome in the present protocol.
The selection of serum TTR as the primary outcome requires careful interpretation. Serum TTR levels may be influenced by protein-energy intake, liver function, inflammatory status, and intercurrent clinical conditions. Accordingly, in this protocol, serum TTR will not be interpreted as a direct surrogate of muscle mass or as a stand-alone measure of clinical efficacy. Rather, it will be considered a serum marker of early metabolic and nutritional response, whose interpretation will be complemented by functional, body composition, inflammatory, and safety-related outcomes.
This study is therefore designed as an exploratory, randomized proof-of-concept trial to determine whether the combination of leucine and seaweed flour improves serum TTR and whether this response is accompanied by consistent secondary changes in muscle strength, mobility, body composition, and the metabolic-inflammatory profile.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: María S Mariotti Celis, Ph D
- Número de teléfono: +56 9 82332421
- Correo electrónico: mmariotti@uft.cl
Ubicaciones de estudio
-
-
-
Santiago, Chile, 8010000
- Universidad Finis Terrae
-
Contacto:
- Cristian R Encina Acosta, Ph D
- Número de teléfono: +56 9 62240100
- Correo electrónico: cencinaa@uft.edu
-
Contacto:
- Conrado S Camilo Manriquez
- Número de teléfono: +56 9 77508471
- Correo electrónico: ccamilo@uft.cl
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria
- Age between 60 and 80 years at the time of enrollment.
- Ability to understand the study procedures and provide written informed consent.
- SARC-F score ≥4 during screening.
- Reduced muscle strength defined as handgrip strength <27 kg in men or <16 kg in women; alternatively, a time >15 seconds on the five-repetition chair stand test when handgrip dynamometry cannot be validly performed or is contraindicated.
- Availability to attend study visits and comply with daily consumption of the study product for 28 days.
- Willingness to provide fasting blood samples at the Day 0 and Day 28 visits. Exclusion Criteria
- Cognitive impairment according to the abbreviated Mini-Mental State Examination (MMSE), using the operational cutoff approved for the study (≤13 points).
- Clinically significant chronic liver disease, clinically significant chronic kidney disease, nephrotic syndrome, active cancer or recent oncological treatment, or any condition that may substantially affect serum TTR levels or increase participant risk.
- Acute infection, acute inflammatory condition, or clinical decompensation at baseline that may interfere with the interpretation of serum TTR measurements.
- Uncontrolled diabetes mellitus or any metabolic condition that, in the investigator's judgment, may increase the risks associated with the intervention.
- Food allergy or intolerance to any component of the study product, including gluten, egg, milk, or other specific cake ingredients.
- Use of leucine, HMB, or protein supplements within the previous 3 months.
- Chronic use of systemic corticosteroids, immunosuppressive agents, or other therapies that may significantly alter the metabolic response under study.
- Untreated thyroid disease or any other unstable endocrine disorder.
- Clinically significant edema, severe dehydration, or any condition that may compromise the validity of bioelectrical impedance measurements.
- Any medical, functional, social, or cognitive condition that may limit safe participation or adherence to the study protocol.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: Control chocolate cake
One daily serving of standard chocolate-flavored cake without added leucine or seaweed flour for 28 consecutive days
|
Participants will consume one standard chocolate-flavored cake serving daily for 28 days, without added leucine or seaweed flour.
Otros nombres:
|
|
Comparador activo: Leucine-enriched chocolate cake
One daily serving of standard chocolate-flavored cake supplemented with 3 g of leucine for 28 consecutive days
|
Participants will consume one chocolate-flavored cake serving supplemented with 3 g of leucine daily for 28 days.
Otros nombres:
|
|
Experimental: Leucine and Durvillaea incurvata Flour-Enriched Chocolate Cake
One daily serving of standard chocolate-flavored cake supplemented with 3 g of leucine and 3 g of Durvillaea incurvata flour for 28 consecutive days.
|
Participants will consume one chocolate-flavored cake serving supplemented with 3 g of leucine and 3 g of Durvillaea incurvata flour daily for 28 days.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline in fasting serum transthyretin concentration at day 28.
Periodo de tiempo: 28 days
|
Fasting serum transthyretin (TTR; prealbumin) concentration (mg/dL) measured using Human Transthyretin/Prealbumin ELISA Kit (NBP2-60516, Bio-Techne, Novus Biologicals).
The outcome is the change from Day 0 to Day 28 according to the Statistical Analysis Plan.
|
28 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline in handgrip strength at day 28.
Periodo de tiempo: 28 days
|
Handgrip strength (kg) measured by dynamometry under standardized conditions.
The operational measure, such as the best of three valid attempts.
|
28 days
|
|
Change from baseline in 4-meter gait speed at day 28.
Periodo de tiempo: 28 days
|
Usual gain speed (m/s) calculated from the 4-meter walk test under standardized condition.
|
28 days
|
|
Change from baseline in appendicular muscle mass index at day 28.
Periodo de tiempo: 28 days
|
Appendicular skeletal muscle mass index (kg/m2) measured calculated as appendicular skeletal muscle mass divided by height squared
|
28 days
|
|
Percentage (%) of prescribed study product serving consumed during the intervention.
Periodo de tiempo: 28 days
|
Adherence calculated from returned product counts and participant self-report as number of consumed servings divided by the number of prescribed servings.
|
28 days
|
|
Number of participants with adequate adherence during the intervention.
Periodo de tiempo: 28 days
|
Participants who consume at least 80% of prescribed study product serving during the 28-day intervention.
|
28 days
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants with any adverse event.
Periodo de tiempo: 28 days
|
Number of participants with at least one adverse event recorded from through the day 28 visit, regardless of relationship to the intervention.
|
28 days
|
|
Number of participants with serious adverse events.
Periodo de tiempo: 28 days
|
Number of participants with at least one serious adverse event, as defined by applicable ethical and regulatory criteria
|
28 days
|
|
Number of participants with treatment-related adverse events
Periodo de tiempo: 28 days
|
Number of participants with at least one adverse event assessed by the investigator as possibly, probably, or definitely related to the assigned study product.
|
28 days
|
|
Number of participants with gastrointestinal intolerance symptoms.
Periodo de tiempo: 28 days
|
Number of participants reporting gastrointestinal symptoms such as nausea, abdominal pain, bloating, diarrhea, constipation, vomiting, or other symptoms recorded in the tolerability form.
|
28 days
|
|
Number of participants who discontinue the study product due to an adverse event.
Periodo de tiempo: 28 days
|
Number of participants who permanently stop consuming the assigned study product because of an adverse event.
|
28 days
|
|
Change from baseline in serum TNF-alpha concentration at day 28.
Periodo de tiempo: 28 days
|
Fasting serum TNF-alpha concentration (pg/mL) measured using Human TNF-alpha ELISA Kit.
|
28 days
|
|
Change from baseline in serum OX-SR1 concentration
Periodo de tiempo: 28 days
|
Fasting serum OX-SR1 concentration (pg/mL) measured using Human Oxidative Stress Responsive (OXSR1) ELISA Kit
|
28 days
|
|
Change from baseline in fasting insulin concentration at day 28.
Periodo de tiempo: 28 days
|
Fasting serum insulin (uUI/mL) measure using the validated assay.
|
28 days
|
|
Change from baseline in total cholesterol concentration at day 28
Periodo de tiempo: 28 days
|
Fasting serum total cholesterol concentration (mg/dL) measured using the laboratory method.
|
28 days
|
|
Change from baseline in LDL cholesterol concentration at day 28.
Periodo de tiempo: 28 days
|
Fasting serum LDL cholesterol concentration (mg/dL) measured using the laboratory method.
|
28 days
|
|
Change from baseline in HDL cholesterol concentration at day 28.
Periodo de tiempo: 28 days
|
Fasting serum HDL cholesterol concentration (mg/dL) measured using the laboratory method.
|
28 days
|
|
Change from baseline in triglyceride concentration at day 28.
Periodo de tiempo: 28 days
|
Fasting serum triglyceride concentration (mg/dL) measured using the laboratory method.
|
28 days
|
|
Change from baseline in serum glucose concentration at day 28.
Periodo de tiempo: 28 days
|
Fasting serum glucose concentration (mg/dL) measured using the laboratory method
|
28 days
|
|
Change from baseline in serum total protein concentration at day 28.
Periodo de tiempo: 28 days
|
Fasting serum total protein concentration (mg/dL) measured using the laboratory method.
|
28 days
|
|
Change from baseline in serum total bilirubin concentration at day 28.
Periodo de tiempo: 28 days
|
Fasting serum total bilirubin concentration (U/L) measured using the laboratory method.
|
28 days
|
|
Change from baseline in serum albumin concentration at day 28.
Periodo de tiempo: 28 days
|
Fasting serum albumin concentration (g/dL) measured using the laboratory method.
|
28 days
|
|
Change from baseline in serum globulin concentration at day 28.
Periodo de tiempo: 28 days
|
Fasting serum globulin concentration (g/dL) measured using the laboratory method.
|
28 days
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, Kojima T, Kuzuya M, Lee JSW, Lee SY, Lee WJ, Lee Y, Liang CK, Lim JY, Lim WS, Peng LN, Sugimoto K, Tanaka T, Won CW, Yamada M, Zhang T, Akishita M, Arai H. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2. doi: 10.1016/j.jamda.2019.12.012. Epub 2020 Feb 4.
- Shenkin A. Serum prealbumin: Is it a marker of nutritional status or of risk of malnutrition? Clin Chem. 2006 Dec;52(12):2177-9. doi: 10.1373/clinchem.2006.077412. No abstract available.
- Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169.
- Calvani R, Marini F, Cesari M, Tosato M, Anker SD, von Haehling S, Miller RR, Bernabei R, Landi F, Marzetti E; SPRINTT consortium. Biomarkers for physical frailty and sarcopenia: state of the science and future developments. J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):278-86. doi: 10.1002/jcsm.12051. Epub 2015 Jul 7.
- Beaudart C, Alcazar J, Aprahamian I, Batsis JA, Yamada Y, Prado CM, Reginster JY, Sanchez-Rodriguez D, Lim WS, Sim M, von Haehling S, Woo J, Duque G; Global Leadership Initiative in Sarcopenia (GLIS) group. Health outcomes of sarcopenia: a consensus report by the outcome working group of the Global Leadership Initiative in Sarcopenia (GLIS). Aging Clin Exp Res. 2025 Mar 22;37(1):100. doi: 10.1007/s40520-025-02995-9.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Manifestaciones neurológicas
- Enfermedades del Sistema Nervioso
- Manifestaciones Neuromusculares
- Condiciones Patológicas, Anatómicas
- Atrofia Muscular
- Atrofia
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Sarcopenia
- Aminoácidos, péptidos y proteínas
- Aminoácidos
- Aminoácidos, esenciales
- Aminoácidos, cadena ramificada
- Leucina
Otros números de identificación del estudio
- 25-124
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .